0001209191-21-009047.txt : 20210209 0001209191-21-009047.hdr.sgml : 20210209 20210209195600 ACCESSION NUMBER: 0001209191-21-009047 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210205 FILED AS OF DATE: 20210209 DATE AS OF CHANGE: 20210209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Poukalov Konstantin CENTRAL INDEX KEY: 0001678736 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39971 FILM NUMBER: 21608653 MAIL ADDRESS: STREET 1: C/O KADMON HOLDINGS, LLC STREET 2: 450 E 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Landos Biopharma, Inc. CENTRAL INDEX KEY: 0001785345 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 815085535 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1800 KRAFT DRIVE, SUITE 216 CITY: BLACKSBURG STATE: VA ZIP: 24060 BUSINESS PHONE: 540-818-2844 MAIL ADDRESS: STREET 1: 1800 KRAFT DRIVE, SUITE 216 CITY: BLACKSBURG STATE: VA ZIP: 24060 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-05 0 0001785345 Landos Biopharma, Inc. LABP 0001678736 Poukalov Konstantin C/O LANDOS BIOPHARMA, INC. 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060 1 0 1 0 Common Stock 2021-02-05 4 P 0 27453 11.14 A 14647181 I By funds Common Stock 2021-02-08 4 P 0 34611 11.38 A 14681792 I By funds Common Stock 2021-02-08 4 P 0 86671 12.53 A 14768463 I By funds Common Stock 2021-02-08 4 P 0 1771 13.10 A 14770234 I By funds Common Stock 2021-02-09 4 P 0 64730 13.80 A 14834964 I By funds Common Stock 2021-02-09 4 P 0 34951 14.60 A 14869915 I By funds The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4. These shares were purchased in multiple transactions at prices ranging from $11.05 to $11.75, inclusive. Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. These shares were purchased in multiple transactions at prices ranging from $10.96 to $11.93, inclusive. These shares were purchased in multiple transactions at prices ranging from $11.96 to $12.95, inclusive. These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.10, inclusive. These shares were purchased in multiple transactions at prices ranging from $13.17 to $14.16, inclusive. These shares were purchased in multiple transactions at prices ranging from $14.17 to $15.20, inclusive. /s/ Eric W. Blanchard, Attorney-in-Fact 2021-02-09